Nuzenio

Tipranks Arcus Biosciences

Tipranks Arcus Biosciences entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 4 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Arcus Biosciences price target raised to $42 from $34 at Goldman Sachs - TipRanksTipRanks · Fri, 07 Aug 2026 10:34:29 GMTArcus Biosciences: Broad Casdatifan Strategy in ccRCC Supports Buy Rating with Unchanged $45 Price Target - TipRanksTipRanks · Thu, 06 Aug 2026 13:19:28 GMTArcus Biosciences reports Q2 EPS (72c), consensus (81c) - TipRanksTipRanks · Thu, 06 Aug 2026 09:52:41 GMTArcus Biosciences price target raised to $29 from $25 at BofA - TipRanksTipRanks · Mon, 03 Aug 2026 15:06:04 GMT

Timeline

Fri, 07 Aug 2026 10:34:29 GMTArcus Biosciences price target raised to $42 from $34 at Goldman Sachs - TipRanks
Thu, 06 Aug 2026 13:19:28 GMTArcus Biosciences: Broad Casdatifan Strategy in ccRCC Supports Buy Rating with Unchanged $45 Price Target - TipRanks
Thu, 06 Aug 2026 09:52:41 GMTArcus Biosciences reports Q2 EPS (72c), consensus (81c) - TipRanks
Mon, 03 Aug 2026 15:06:04 GMTArcus Biosciences price target raised to $29 from $25 at BofA - TipRanks

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tipranks Arcus Biosciences.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.